Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

20, Novartis Investigational Site, Santiago de Compostela

11, Novartis Investigational Site, Genova

10, Novartis Investigational Site, Milan

22, Novartis Investigational Site, Madrid

14, Novartis Investigational Site, Padua

23, Novartis Investigational Site, Madrid

24, Novartis Investigational Site, Valencia

12, Novartis Investigational Site, Florence

42, Novartis Investigational Site, Moscow

41, Novartis Investigational Site, Moscow

43, Novartis Investigational Site, Yekaterinburg

13, Novartis Investigational Site, Roma

31, Novartis Investigational Site, Krakow

33, Novartis Investigational Site, Warsaw

30, Novartis Investigational Site, Wroclaw

21, Novartis Investigational Site, Barcelona

53, Novartis Investigational Site, London

52, Novartis Investigational Site, Manchester

50, Novartis Investigational Site, Oxford

51, Novartis Investigational Site, Southampton